Screener
Celldex Therapeutics CLDX Q2 2026 earnings
Reported August 6, 2026 · After market close
Revenue$22.0KMiss by $712.9K
EPS-$0.94Beat by $0.12
Revenue estimate$734.9K
EPS estimate-$1.06
“We are leaders in mast cell science with a pipeline of programs that have the potential to dramatically shift treatment paradigms for patients. Barzolvolimab, followed by our first bispecific candidate CDX-622, are a powerful portfolio combination targeting inflammatory diseases where mast cells are implicated, with the goal of ultimately bringing our leading science to additional patient populations that could benefit from our medicines. We are looking forward to sharing the topline results from our two Phase 3 trials of barzolvolimab in the early fall and are actively driving towards potential commercialization.”
Next report
Nov 9, 2026 (in 2 months)Revenue estimate$722.6K
EPS estimate-$1.02
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Celldex Therapeutics report Q2 2026 earnings?
- Celldex Therapeutics (CLDX) reported Q2 2026 earnings on August 6, 2026 after market close.
- What were Celldex Therapeutics's Q2 2026 revenue and EPS?
- Celldex Therapeutics reported revenue of $22.0K and eps of $-0.94 for Q2 2026.
- Did Celldex Therapeutics beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $734.9K by $712.9K. EPS beat the consensus estimate of $-1.06 by $0.12.
- How did Celldex Therapeutics's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 97.0% from $730.0K a year earlier and eps declined 10.6% from $-0.85.
- Where can I find Celldex Therapeutics's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001171843-26-005316) and the 10-Q periodic report (0001104659-26-091984) directly on SEC EDGAR. The filing index links above go to sec.gov.
